Categories

Semaglutide Impurities, des-20-1-AEEA,20-2-AEEA,20-3-γ-Glu, 20-4-Octadecanedioic Acid-SMT

Semaglutide impurities include des-20-1-AEEA, 20-2-AEEA, 20-3-γ-Glu and 20-4-Octadecanedioic Acid-SMT, which are specific structural derivatives produced during the synthesis or degradation of semaglutide. Semaglutide is a GLP-1 receptor agonist, mainly used to treat type 2 diabetes and obesity. These impurities may be formed by amino acid deletion (such as des-20-1-AEEA), side chain modification (such as AEEA or γ-glutamyl group connection) or fatty acid chain changes (such as octadecane dioic acid replacement). Their presence may affect the purity and efficacy of the drug and needs to be strictly monitored in quality control.

  • Product Details

  • Technical Support

Product Overview

Basic Description

Structure and function:
1. des-20-1-AEEA,20-2-AEEA,20-3-γ-Glu, 20-4-Octadecanedioic Acid-SMT is an impurity of semaglutide that lacks all modifications of lysine at position 20 (AEEA-AEEA-γ-Glu-octadecanediolic acid).
2. It is a GLP-1 receptor agonist that regulates blood glucose levels by mimicking intestinal secretion of glucagon-like peptide-1 (GLP-1).
3. Due to the lack of all modified moieties, its biological activity and pharmacokinetic properties may differ from those of semaglutide.
In vitro and in vivo studies:
1. In vitro studies have shown that des-20-1-AEEA, 20-2-AEEA, 20-3-γ-Glu, 20-4-Octadecanedioic Acid-SMT can still bind to and activate GLP-1 receptors, but their affinity and potency may be significantly reduced.
2. In vivo studies have shown that the hypoglycemic effect of this impurity in animal models is weaker than that of semaglutide, and its half-life may be shorter.
3. Preclinical studies have shown that des-20-1-AEEA, 20-2-AEEA, 20-3-γ-Glu, 20-4-Octadecanedioic Acid-SMT may cause adverse reactions or decreased efficacy in some cases.

​Three-letter sequence​

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys-Ile-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2

​Single letter sequence​

HHAEGTFTSDVSSYLEGQAKITWLVLVKGDVRRAARRRRG-NH2

Molecular formula

C178H272N46O51S

Molecular weight

3866.10 g/mol

Product Attributes

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light


Instructions
  • Please store the product immediately according to the recommended conditions in the instructions upon receipt. Unless otherwise specified, all products are freeze-dried powders. Since trace amounts of peptides are deposited in the tube during the freeze-drying process, forming a very thin or invisible peptide layer, we recommend centrifuging at about 8,000-12,000g for 10-30 seconds in a centrifuge before opening the tube cap, so that the peptides attached to the tube cap or tube wall are aggregated at the bottom of the tube.
  • Please refer to relevant literature for the specific optimal working concentration, or explore and optimize through experiments based on the purpose of the experiment and specific cells and animals.
Our company can provide customized synthesis of high-polypeptide, virtual screening of compounds, Animal disease model construction,
Drug safety verification,
Application technology support for gene editing animals, etc.
For specific application consultation, please contact the sales department.

We look forward to your inquiries:

Sales Department 1: Manager Han
Mobile phone: 18701856899
WeChat: 18701856899
QQ: 1295139147
Email: 18701856899@163.com